Developing Novel Therapies from Neonatal Cardiac Progenitor Cells (nCPCs)
nCPC: The Ideal Stem Cell for Clinical Development
Manufacturing Consistency
Adult stem cells exhibit significant variability from person to person, making it difficult to achieve the consistency required by the U.S. FDA for drug development. Our lead drug, STM-01, and its secretome, STM-21, are derived from neonatal sources (babies under 30 days old), ensuring near-zero variability. This breakthrough eliminates a key challenge in producing reliable, scalable stem cell-based therapies.
Maximal Potency
The regenerative potential of stem cells decreases with age—cells from older donors are less potent than those from younger donors. This is why we heal quickly when we’re young, and more slowly as we age. In head-to-head studies published in peer-reviewed journals, our lead nCPC, STM-01, has proven significantly more potent than any adult-derived stem cell.
Scale and Cost of Goods
Exponentially more nCPCs can be produced from a single donor compared to adult cells, driving down production costs and minimizing the number of donors needed.
Non-Fetal Source
While embryonic or fetal stem cells also possess minimal inter-donor variability, their use is complicated by ethical and political considerations. Cells sourced from neonates avoid these issues while maintaining their potency and manufacturing advantages.
Learn More About Our Ongoing Clinical Studies
Contact Information
Baltimore Office
323 W. Camden Street, Suite 600
Baltimore, MD 21201
Chicago Lab
400 N. Aberdeen Street, Suite 900
Chicago, IL 60642
Plano Office
7250 Dallas Parkway, Suite 400
Plano, TX 75024